Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy
Status:
NOT_YET_RECRUITING
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy. Participants will take both the study drug and a placebo in two separate periods, with a wash-out period in between. The goal is to determine whether Enavogliflozin is safe and effective for treating amyloid cardiomyopathy.